MindWalk (NASDAQ:HYFT – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.
Valuation and Earnings
This table compares MindWalk and 10x Genomics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MindWalk | $16.23 million | 3.80 | -$10.11 million | ($0.26) | -5.07 |
| 10x Genomics | $616.91 million | 16.02 | -$43.54 million | ($0.59) | -128.59 |
Insider & Institutional Ownership
6.7% of MindWalk shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
MindWalk has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
Profitability
This table compares MindWalk and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MindWalk | -105.11% | -133.26% | -77.78% |
| 10x Genomics | -12.18% | -9.33% | -7.30% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for MindWalk and 10x Genomics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MindWalk | 2 | 0 | 2 | 1 | 2.40 |
| 10x Genomics | 1 | 11 | 5 | 0 | 2.24 |
MindWalk currently has a consensus target price of $5.00, indicating a potential upside of 279.08%. 10x Genomics has a consensus target price of $44.00, indicating a potential downside of 42.00%. Given MindWalk’s stronger consensus rating and higher possible upside, equities analysts clearly believe MindWalk is more favorable than 10x Genomics.
Summary
10x Genomics beats MindWalk on 9 of the 15 factors compared between the two stocks.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.
